Cell Source, Inc. (33)
Browse by Contract Category
Contracts
-
10% Convertible Note issued to George Verstraete
(Filed With SEC on April 15, 2022)
-
Eighth Amendment to Research and License Agreement dated as of December 2, 2021 between the Company and Yeda Research and Development Company Limited
(Filed With SEC on April 15, 2022)
-
Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between the University of Texas MD Anderson Cancer Center and Cell Source Ltd
(Filed With SEC on April 15, 2022)
-
CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT
(Filed With SEC on August 14, 2019)
-
Fifth Amendment to Research and License Agreement dated as of June 30, 2019 between the Company and Yeda Research and Development Company Limited
(Filed With SEC on April 15, 2022)
-
Description of Common Stock
(Filed With SEC on April 15, 2022)
-
Amendment No. 2 to Sponsored Research Agreement dated October 18, 2021 between The University of Texas M.D. Anderson Cancer Center and Cell Source Limited
(Filed With SEC on November 15, 2021)
-
Third Amended and Restated 10.0% Convertible Note
(Filed With SEC on August 12, 2021)
-
Seventh Amendment to Research and License Agreement dated November 15, 2020 between Yeda Research and Development Company Limited and Cell Source Limited
(Filed With SEC on April 15, 2021)
-
Form of warrant issued to holder of Second Amended and Restated 10.0% Convertible Note
(Filed With SEC on April 15, 2021)
-
Second Amended and Restated 10.0% Convertible Note
(Filed With SEC on April 15, 2021)
-
Form of Note Exchange Agreement between Cell Source, Inc. and holder of 10% OID Convertible Promissory Note
(Filed With SEC on April 15, 2021)
-
Form of Warrant issued to Service Providers
(Filed With SEC on November 13, 2020)
-
Form of Warrant issued to Purchasers of 8% Convertible Promissory Note
(Filed With SEC on November 13, 2020)
-
Form of 8% Convertible Promissory Note
(Filed With SEC on November 13, 2020)
-
Form of Consultant Stock Option Agreement
(Filed With SEC on November 13, 2020)
-
Form of Director Stock Option Agreement
(Filed With SEC on November 13, 2020)
-
Form of Warrant issued to Members of Scientific Advisory Board
(Filed With SEC on November 13, 2020)
-
Form of Warrant issued to purchaser of 10% OID Convertible Promissory Note
(Filed With SEC on August 14, 2020)
-
Form of 10% OID Convertible Promissory Note
(Filed With SEC on August 14, 2020)
-
Form of Securities Purchase Agreement between Cell Source, Inc. and the purchaser of 10% OID Convertible Promissory Note
(Filed With SEC on August 14, 2020)
-
Form of Placement Agent Warrant dated February 13, 2020
(Filed With SEC on May 15, 2020)
-
Convertible Promissory Note dated January 10, 2020
(Filed With SEC on May 15, 2020)
-
Sixth Amendment to Research and License Agreement effective December 31, 2019 between Yeda Research and Development Company Limited and Cell Source Limited
(Filed With SEC on March 30, 2020)
-
Convertible Note effective October 28, 2019
(Filed With SEC on March 30, 2020)
-
(Filed With SEC on August 14, 2019)
-
(Filed With SEC on August 14, 2019)
-
(Filed With SEC on August 14, 2019)
-
CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT
(Filed With SEC on August 14, 2019)
-
CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN
(Filed With SEC on August 14, 2019)
-
AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT
(Filed With SEC on May 20, 2019)
-
SPONSORED RESEARCH AGREEMENT
(Filed With SEC on April 1, 2019)
-
ยง 1 Subject matter
(Filed With SEC on April 1, 2019)
